AR118724A1 - Inhibidores de dihidroorotato deshidrogenasa - Google Patents
Inhibidores de dihidroorotato deshidrogenasaInfo
- Publication number
- AR118724A1 AR118724A1 ARP200101096A ARP200101096A AR118724A1 AR 118724 A1 AR118724 A1 AR 118724A1 AR P200101096 A ARP200101096 A AR P200101096A AR P200101096 A ARP200101096 A AR P200101096A AR 118724 A1 AR118724 A1 AR 118724A1
- Authority
- AR
- Argentina
- Prior art keywords
- group
- alkyl
- och3
- substituted
- haloalkyl
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
- A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Hydrogenated Pyridines (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
Reivindicación 1: Un compuesto que tiene la estructura de la fórmula (1) en donde X es CH o N; Y es CH o N; R¹ se selecciona del grupo que consiste en: alquilo C₁₋₆; alquilo C₁₋₆ sustituido con OH u OCH₃; alquenilo C₂₋₆; haloalquilo C₁₋₆; haloalquilo C₁₋₆ sustituido con OH u OCH₃; haloalquenilo C₂₋₆; N(CH₃)₂; cicloalquilo C₃₋₆; cicloalquilo C₃₋₆ sustituido con alquilo C₁₋₆; y fenilo; R² es un compuesto de fórmula (2); en donde Rᵃ se selecciona del grupo que consiste en: alquilo C₁₋₆, haloalquilo C₁₋₆ y cicloalquilo C₃₋₆; Rᵇ es alquilo C₁₋₆ o alquilo C₁₋₆ sustituido con un miembro seleccionado del grupo que consiste en: OH, halo, CN, O-alquilo C₁₋₆, O-haloalquilo C₁₋₆ y O-cicloalquilo C₃₋₆; R³ se selecciona del grupo que consiste en: H, halo, CH₃ y OCH₃; R⁴ se selecciona del grupo que consiste en: (e) alquilo C₁₋₆; alquilo C₁₋₆ sustituido con uno o dos OCH₃; cicloalquilo C₃₋₆; cicloalquilo C₃₋₆ sustituido con CH₃ u OCH₃; CH₂-cicloalquilo C₃₋₆; y el resto de fórmula (3); (f) un resto de fórmula (4); (g) un resto seleccionado del grupo de fórmulas (5); y (h) un resto del grupo de fórmulas (6); en donde cada Rᶜ se selecciona independientemente del grupo que consiste en: H; halo; alquilo C₁₋₆; alquilo C₁₋₆ sustituido con un miembro seleccionado del grupo que consiste en: OH, OCH₃, SCH₃ y OCF₃; haloalquilo C₁₋₆; haloalquilo C₁₋₆ sustituido con un miembro seleccionado del grupo que consiste en: OH y OCH₃; NO₂; OH; O-CH₂CH₂OH; u O-alquilo C₁₋₆; Rᵈ se selecciona del grupo que consiste en: H; halo; alquilo C₁₋₆; alquilo C₁₋₆ sustituido con un miembro seleccionado del grupo que consiste en: OH, OCH₃, SCH₃ y OCF₃; haloalquilo C₁₋₆; haloalquilo C₁₋₆ sustituido con un miembro seleccionado del grupo que consiste en: OH y OCH₃; CN; u O-alquilo C₁₋₆; Rᵍ se selecciona del grupo que consiste en: H; alquilo C₁₋₆; alquilo C₁₋₆ sustituido con un miembro seleccionado del grupo que consiste en: OH, OCH₃, SCH₃ y OCF₃; haloalquilo C₁₋₆; y haloalquilo C₁₋₆ sustituido con un miembro seleccionado del grupo que consiste en: OH y OCH₃; y n es 1, ó 2; o una sal, isótopo, N-óxido, solvato o estereoisómero farmacéuticamente aceptables de estos.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962835113P | 2019-04-17 | 2019-04-17 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR118724A1 true AR118724A1 (es) | 2021-10-27 |
Family
ID=70465152
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP200101096A AR118724A1 (es) | 2019-04-17 | 2020-04-17 | Inhibidores de dihidroorotato deshidrogenasa |
Country Status (22)
| Country | Link |
|---|---|
| US (2) | US11505536B2 (es) |
| EP (1) | EP3956320B1 (es) |
| JP (1) | JP7566776B2 (es) |
| KR (1) | KR20220002964A (es) |
| CN (1) | CN114174278B (es) |
| AR (1) | AR118724A1 (es) |
| AU (1) | AU2020259384A1 (es) |
| BR (1) | BR112021020520A2 (es) |
| CA (1) | CA3136791A1 (es) |
| CL (1) | CL2021002681A1 (es) |
| CO (1) | CO2021015264A2 (es) |
| CR (1) | CR20210520A (es) |
| EC (1) | ECSP21081726A (es) |
| ES (1) | ES2968809T3 (es) |
| IL (1) | IL287268A (es) |
| MA (1) | MA55716A (es) |
| MX (1) | MX2021012706A (es) |
| PE (1) | PE20220761A1 (es) |
| SG (1) | SG11202111179RA (es) |
| TW (1) | TW202104207A (es) |
| UY (1) | UY38670A (es) |
| WO (1) | WO2020212897A1 (es) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3184985A1 (en) * | 2020-07-14 | 2022-01-20 | Nanjing Zenshine Pharmaceuticals Co., Ltd. | Compounds as dhodh inhibitors |
| WO2022070068A1 (en) * | 2020-09-30 | 2022-04-07 | Janssen Biotech, Inc. | Dihydroorotate dehydrogenase inhibitors |
| WO2022074534A1 (en) * | 2020-10-05 | 2022-04-14 | Janssen Biotech, Inc. | Combinations of dihydroorotate dehydrogenase inhibitors and hypomethylating agents |
| WO2022200615A1 (en) | 2021-03-26 | 2022-09-29 | Georg-August-Universität Göttingen Stiftung Öffentlichen Rechts, Universitätsmedizin | Pyrimidine biosynthesis inhibitor combination for use in treating viral infections |
| CN117337180A (zh) | 2021-05-11 | 2024-01-02 | 詹森药业有限公司 | 组合疗法 |
| MX2023013410A (es) | 2021-05-11 | 2023-12-06 | Janssen Pharmaceutica Nv | Terapias de combinacion. |
| KR20240102967A (ko) * | 2021-10-13 | 2024-07-03 | 레믹스 테라퓨틱스 인크. | 스플라이싱을 조절하기 위한 화합물 및 방법 |
| EP4429663A1 (en) * | 2021-11-09 | 2024-09-18 | Vigil Neuroscience, Inc. | Heterocyclic compounds as triggering receptor expressed on myeloid cells 2 agonists |
| WO2024114664A1 (en) | 2022-11-30 | 2024-06-06 | Janssen Pharmaceutica Nv | Combinations comprising a menin-mll inhibitor and at least one other therapeutic agent |
| WO2024114666A1 (en) | 2022-11-30 | 2024-06-06 | Janssen Pharmaceutica Nv | Combinations comprising a menin-mll inhibitor and a bcl-2 inhibitor |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2005219791B2 (en) * | 2004-03-05 | 2011-06-09 | Msd K.K. | Diaryl-substituted five-membered heterocycle derivative |
| JP2007015952A (ja) * | 2005-07-06 | 2007-01-25 | Shionogi & Co Ltd | ナフタレン誘導体 |
| CN101641013B (zh) | 2007-01-22 | 2014-07-30 | Gtx公司 | 核受体结合剂 |
| FI3640241T3 (fi) * | 2013-10-18 | 2023-01-13 | Bromodomeeni-inhibiittorit | |
| MY197533A (en) * | 2014-09-19 | 2023-06-21 | Forma Therapeutics Inc | Pyridin-2(1h)-one quinolinone derivatives as mutant-isocitrate dehydrogenase inhibitors |
| PL3233857T3 (pl) | 2014-12-18 | 2020-07-27 | Takeda Pharmaceutical Company Limited | Stałe postacie skondensowanych heteroaromatycznych pirolidynonów |
| JOP20190094A1 (ar) | 2016-10-27 | 2019-04-25 | Broad Inst Inc | مركبات 1، 2، 4-تريازولون تحمل ثلاثة بدائل عند المواقع 2، 4، 5 مفيدة كمثبطات لديهيدروجيناز ثنائي هيدرو أوروتات (dhodh) |
| JP2019535689A (ja) | 2016-10-27 | 2019-12-12 | バイエル アクチェンゲゼルシャフトＢａｙｅｒ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ | ４，５−縮環１，２，４−トリアゾロン |
| AU2018223982B2 (en) | 2017-02-24 | 2022-02-03 | Merck Patent Gmbh | 1, 4, 6-trisubstituted-2-alkyl-1H-benzo[d]imidazole derivatives as dihydroorotate oxygenase inhibitors |
| CA3094104A1 (en) | 2018-03-26 | 2019-10-03 | Clear Creek Bio, Inc. | Methods of determining dosing of a therapeutic agent based on measured levels of a metabolite |
| TW202043208A (zh) | 2019-01-11 | 2020-12-01 | 美商健生生物科技公司 | 二氫乳清酸脫氫酶抑制劑 |
| BR112021014456A2 (pt) | 2019-02-07 | 2021-09-21 | Janssen Biotech, Inc. | Inibidores de di-hidro-orotato desidrogenase |
-
2020
- 2020-04-15 TW TW109112585A patent/TW202104207A/zh unknown
- 2020-04-16 MA MA055716A patent/MA55716A/fr unknown
- 2020-04-16 CN CN202080046006.6A patent/CN114174278B/zh active Active
- 2020-04-16 PE PE2021001728A patent/PE20220761A1/es unknown
- 2020-04-16 CR CR20210520A patent/CR20210520A/es unknown
- 2020-04-16 JP JP2021561703A patent/JP7566776B2/ja active Active
- 2020-04-16 SG SG11202111179RA patent/SG11202111179RA/en unknown
- 2020-04-16 ES ES20721759T patent/ES2968809T3/es active Active
- 2020-04-16 US US16/850,171 patent/US11505536B2/en active Active
- 2020-04-16 WO PCT/IB2020/053601 patent/WO2020212897A1/en unknown
- 2020-04-16 CA CA3136791A patent/CA3136791A1/en active Pending
- 2020-04-16 BR BR112021020520A patent/BR112021020520A2/pt not_active Application Discontinuation
- 2020-04-16 KR KR1020217037263A patent/KR20220002964A/ko unknown
- 2020-04-16 AU AU2020259384A patent/AU2020259384A1/en not_active Abandoned
- 2020-04-16 MX MX2021012706A patent/MX2021012706A/es unknown
- 2020-04-16 EP EP20721759.7A patent/EP3956320B1/en active Active
- 2020-04-17 UY UY0001038670A patent/UY38670A/es unknown
- 2020-04-17 AR ARP200101096A patent/AR118724A1/es unknown
-
2021
- 2021-10-13 CL CL2021002681A patent/CL2021002681A1/es unknown
- 2021-10-14 IL IL287268A patent/IL287268A/en unknown
- 2021-11-11 CO CONC2021/0015264A patent/CO2021015264A2/es unknown
- 2021-11-16 EC ECSENADI202181726A patent/ECSP21081726A/es unknown
-
2022
- 2022-05-12 US US17/742,606 patent/US11753393B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| TW202104207A (zh) | 2021-02-01 |
| SG11202111179RA (en) | 2021-11-29 |
| US20200331881A1 (en) | 2020-10-22 |
| US11505536B2 (en) | 2022-11-22 |
| EP3956320B1 (en) | 2023-11-29 |
| JP7566776B2 (ja) | 2024-10-15 |
| KR20220002964A (ko) | 2022-01-07 |
| PE20220761A1 (es) | 2022-05-16 |
| WO2020212897A1 (en) | 2020-10-22 |
| UY38670A (es) | 2020-10-30 |
| CA3136791A1 (en) | 2020-10-22 |
| ECSP21081726A (es) | 2021-12-30 |
| CN114174278B (zh) | 2024-08-23 |
| MX2021012706A (es) | 2022-01-31 |
| JP2022530203A (ja) | 2022-06-28 |
| BR112021020520A2 (pt) | 2021-12-07 |
| CN114174278A (zh) | 2022-03-11 |
| CO2021015264A2 (es) | 2021-11-19 |
| US11753393B2 (en) | 2023-09-12 |
| IL287268A (en) | 2021-12-01 |
| US20220298137A1 (en) | 2022-09-22 |
| CR20210520A (es) | 2021-12-20 |
| ES2968809T3 (es) | 2024-05-14 |
| AU2020259384A1 (en) | 2021-11-11 |
| EP3956320A1 (en) | 2022-02-23 |
| CL2021002681A1 (es) | 2022-05-27 |
| MA55716A (fr) | 2022-02-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR118724A1 (es) | Inhibidores de dihidroorotato deshidrogenasa | |
| AR112797A1 (es) | Inhibidores de kras g12c y métodos para utilizarlos | |
| AR107519A1 (es) | Compuestos de piperidina sustituido y su uso | |
| AR114793A1 (es) | Moduladores de enzimas modificadoras de metilo, composiciones y usos de los mismos | |
| AR125414A2 (es) | INHIBIDORES DE INTEGRINA avb6 | |
| AR121044A1 (es) | Inhibidores de egfr | |
| AR119698A2 (es) | Compuesto amida n-urea sustituida derivado de aminoácido | |
| AR108710A1 (es) | Compuestos modulares de fxr (nr1h4) | |
| AR090868A1 (es) | Composiciones plaguicidas y procesos relacionados con ellas | |
| AR101586A1 (es) | Derivados heterocíclicos con sustituyentes que contienen azufre activos como plaguicidas | |
| AR081058A1 (es) | Derivados de arilmetoxi isoindolina, composiciones que los comprenden y su uso en el tratamiento del cancer. | |
| AR101815A1 (es) | Compuestos y composiciones como inhibidores de quinasa | |
| CU23926B1 (es) | Derivado de oxopirazina y herbicida | |
| AR085410A1 (es) | Derivados de pirazol heteroaril-sustituidos, composiciones pesticidas que los comprenden y su uso en el control de plagas | |
| AR053774A1 (es) | Derivados de sulfonilbencimidazol. composiciones farmaceuticas. | |
| AR107170A1 (es) | Compuestos heterocíclicos tricíclicos condesados como inhibidores de integrasa del vih | |
| AR107738A1 (es) | Amidas de ácido n-(5-halógen-1,3,4-oxadiazol-2-il)arilcarboxílico y su uso como herbicidas | |
| AR108778A1 (es) | Compuestos antibacterianos | |
| AR090091A1 (es) | Sulfin- y sulfonimidoilbenzamidas de accion herbicida | |
| AR114374A1 (es) | Compuestos herbicidas | |
| AR114430A1 (es) | Compuestos herbicidas | |
| AR112333A1 (es) | Pirrolopirimidina y derivados de pirrolopirimidina | |
| AR089814A1 (es) | Compuestos que modulan la actividad de los proteasomas | |
| AR098101A1 (es) | Composiciones plaguicidas y métodos relacionados | |
| AR119453A1 (es) | Derivados de piridazina |